ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Livmoniplimab
Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Budigalimab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-24

Lead Sponsor: AbbVie

Target Recruit Count: 840

Registration Number: NCT06236438

Locations: 🇺🇸
Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸
Bond Clinic /ID# 262611, Winter Haven, Florida, United States
🇺🇸
University Cancer & Blood Cent /ID# 261824, Athens, Georgia, United States

and more 26 locations

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Subcutaneous (SC) ABBV-383
Drug: Intravenous (IV) ABBV-383

First Posted Date: 2024-01-25

Last Posted Date: 2024-12-24

Lead Sponsor: AbbVie

Target Recruit Count: 55

Registration Number: NCT06223516

Locations: 🇺🇸
Atrium Health Wake Forest Baptist Medical Center /ID# 260807, Winston-Salem, North Carolina, United States
🇩🇪
Universitaetsklinikum Frankfurt /ID# 260442, Frankfurt am Main, Hessen, Germany
🇩🇪
Universitaetsklinikum Hamburg-Eppendorf /ID# 260444, Hamburg, Germany

and more 5 locations

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Phase 4

Completed

Conditions: Upper Facial Lines

Interventions: Drug: BOTOX

First Posted Date: 2024-01-23

Last Posted Date: 2025-01-10

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT06218251

Locations: 🇺🇸
Skin Wellness Dermatology - Homewood /ID# 248469, Birmingham, Alabama, United States
🇺🇸
The Research Center at The Maas Clinic /ID# 256633, San Francisco, California, United States
🇺🇸
Pacific Clinical Innovations /ID# 248467, Vista, California, United States

and more 7 locations

A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Phase 3

Active, not recruiting

Conditions: Forehead Lines

Interventions: Drug: Placebo
Drug: BOTOX

First Posted Date: 2023-12-18

Last Posted Date: 2024-04-17

Lead Sponsor: AbbVie

Target Recruit Count: 140

Registration Number: NCT06174688

Locations: 🇨🇳
Peking University First Hospital /ID# 249912, Xicheng District, Beijing, China
🇨🇳
West China Hospital, Sichuan University /ID# 250474, Chengdu, Sichuan, China
🇨🇳
Beijing Hospital /ID# 250059, Beijing, Beijing, China

and more 9 locations

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

Phase 1

Recruiting

Conditions: Immunoglobulin Light Chain (AL) Amyloidosis

Interventions: Drug: ABBV-383

First Posted Date: 2023-12-06

Last Posted Date: 2024-11-18

Lead Sponsor: AbbVie

Target Recruit Count: 76

Registration Number: NCT06158854

Locations: 🇮🇹
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 255654, Bologna, Emilia-Romagna, Italy
🇺🇸
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida, United States
🇺🇸
Boston Medical Center /ID# 255066, Boston, Massachusetts, United States

and more 14 locations

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: ABBV-383
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Elotuzumab
Drug: Selinexor
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-12-06

Last Posted Date: 2024-11-04

Lead Sponsor: AbbVie

Target Recruit Count: 380

Registration Number: NCT06158841

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸
Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸
Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States

and more 80 locations

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: ABBV-303
Drug: Budigalimab

First Posted Date: 2023-12-06

Last Posted Date: 2024-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 192

Registration Number: NCT06158958

Locations: 🇺🇸
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943, New York, New York, United States
🇺🇸
City of Hope /ID# 254303, Duarte, California, United States
🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 266792, Irvine, California, United States

and more 15 locations

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Phase 1

Completed

Conditions: Moderate to Severe Glabellar Lines

Interventions: Drug: Placebo
Drug: AGN-151586

First Posted Date: 2023-11-30

Last Posted Date: 2024-04-04

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT06151561

Locations: 🇯🇵
Tokyo Center Clinic /ID# 257898, Central District, Tokyo, Japan

A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

Phase 2

Active, not recruiting

Conditions: Skin Quality Deficit

Interventions: Device: ELAPR002f Injectable Gel

First Posted Date: 2023-11-30

Last Posted Date: 2024-08-12

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT06151535

Locations: 🇮🇹
CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 226370, Verona, Italy

Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy

Active, not recruiting

Conditions: Spasticity

First Posted Date: 2023-11-29

Last Posted Date: 2024-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 107

Registration Number: NCT06150729

Locations: 🇲🇽
Hospital General ISSSTE Tacuba /ID# 261460, Ciudad de México, Ciudad De Mexico, Mexico
🇲🇽
Cri Dif Jalisco /Id# 261459, Guadalajara, Mexico
🇲🇽
Hospital General Regional 180 IMSS /ID# 261458, Guadalajara, Jalisco, Mexico

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy